Genomics-guided discovery of a new and significantly better source of anticancer natural drug FK228
FK228 is an FDA-approved anticancer drug naturally produced by Chromobacterium violaceum No. 968 up to 19 mg/L in a pilot industry-scale batch fermentation. Here we report a genomics-guided discovery of Burkholderia thailandensis MSMB43 as a new and significantly better source of FK228. The genome o...
Main Authors: | Xiangyang Liu, Feng Xie, Leah B. Doughty, Qi Wang, Lixin Zhang, Xueting Liu, Yi-Qiang Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2018-12-01
|
Series: | Synthetic and Systems Biotechnology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405805X18300619 |
Similar Items
-
Mechanistic studies of DepR in regulating FK228 biosynthesis in Chromobacterium violaceum no. 968.
by: Yongjian Qiao, et al.
Published: (2018-01-01) -
The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication.
by: Angelika Danielsson, et al.
Published: (2011-01-01) -
Preliminary supplement to the FK 4 (FK SUP)
Published: (1963) -
Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit In Vivo Therapeutic Efficacy against Cryptococcus
by: Michael J. Hoy, et al.
Published: (2022-06-01) -
Cover_228
Published: (2023-04-01)